Related Experiment Video

Updated: Jul 18, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Cytotoxic-free treatment designs: time to resistance

Justin Stebbing, Tim Crook

    Nature Clinical Practice. Oncology
    |December 22, 2006
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
    08:59

    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

    Published on: December 11, 2017

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
    09:19

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

    Published on: February 6, 2015

    Related Experiment Videos

    Last Updated: Jul 18, 2026

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
    08:46

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

    Published on: December 9, 2015

    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
    08:59

    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

    Published on: December 11, 2017

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
    09:19

    Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

    Published on: February 6, 2015

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Cancer-associated fibroblasts as key regulators of lipid metabolism in the tumour microenvironment.

    Oncogene·2026

    The Impact of Study Size on COVID-19 Treatment Outcomes: A Meta-Epidemiological Study Comparing Large and Small Randomized Controlled Trials: A Systematic Review and Meta-Analyses.

    Reviews in medical virology·2026

    Modelling adipose tissue-cancer crosstalk: a three-dimensional perspective.

    Oncogene·2026

    Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

    Journal for immunotherapy of cancer·2025

    Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor.

    Oncogene·2025

    Preserving Fossilized Soft Tissues: Advancing Proteomics and Unveiling the Evolutionary History of Cancer in Dinosaurs.

    Biology·2025

    Effect of bisphosphonates on pain and quality of life in patients with bone metastases.

    Nature clinical practice. Oncology·2009

    Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.

    Nature clinical practice. Oncology·2009

    Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck.

    Nature clinical practice. Oncology·2009

    Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.

    Nature clinical practice. Oncology·2009

    Xoft Axxent electronic brachytherapy: a new device for delivering brachytherapy to the breast.

    Nature clinical practice. Oncology·2009

    Unintended pregnancy during radiotherapy for cancer.

    Nature clinical practice. Oncology·2009

    CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 - GRACIE trial.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026

    [Predictors of treatment-free remission (TFR) and second TFR attempts in chronic myeloid leukemia].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [Aplastic anemia developed after treatment with durvalumab].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [Development of memory-like CAR-NK cells with durable antitumor activity].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

    The American journal of gastroenterology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us